View ValuationSNDL 향후 성장Future 기준 점검 0/6SNDL은 연간 수입과 매출이 각각 138.4%와 3.8% 증가할 것으로 예상되고 EPS는 연간 58%만큼 증가할 것으로 예상됩니다.핵심 정보138.4%이익 성장률57.96%EPS 성장률Pharmaceuticals 이익 성장31.8%매출 성장률3.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트30 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesRecent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.공시 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026공시 • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.공시 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.공시 • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.공시 • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025공시 • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.공시 • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025이익 및 매출 성장 예측CNSX:SNDL - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,000N/AN/AN/A112/31/2027951112174212/31/2026922-6287723/31/2026937-115367N/A12/31/2025946-165871N/A9/30/2025952-925870N/A6/30/2025944-985061N/A3/31/2025928-1074959N/A12/31/2024920-954455N/A9/30/2024911-1103444N/A6/30/2024912-1134049N/A3/31/2024916-1362635N/A12/31/2023909-168-25-17N/A9/30/2023901-211-11-1N/A6/30/2023894-287-29-20N/A3/31/2023886-331-41-29N/A12/31/2022712-335-18-7N/A9/30/2022495-266-38-30N/A6/30/2022278-151-101-95N/A3/31/202264-130-152-147N/A12/31/202156-227-160-156N/A9/30/202147-228-176-173N/A6/30/202146-316-140-137N/A3/31/202157-296-80-78N/A12/31/202061-200-61-57N/A9/30/202062-170-123-101N/A6/30/202077-184-157-109N/A3/31/202076-164-189-107N/A12/31/201964-143N/A-113N/A9/30/201949-156N/A-75N/A6/30/201921-84N/A-49N/A3/31/20191-77N/A-49N/A12/31/2018N/A-68N/A-31N/A2/28/2018N/A-13N/A-5N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SNDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: SNDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: SNDL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: SNDL 의 수익(연간 3.8%)이 Canadian 시장(연간 4.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SNDL 의 수익(연간 3.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SNDL의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 14:24종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SNDL Inc.는 9명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkDavid KideckelATB Cormark6명의 분석가 더 보기
Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
공시 • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
공시 • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).
New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
공시 • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.
Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
공시 • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.
공시 • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025
공시 • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).
Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.
공시 • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025